Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.

Abstract	Decitabine (DAC) is commonly used for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Previous studies have indicated DAC sequentially combined with idarubicin was an effective treatment for myeloid neoplasms. Therefore, a clinical study was conducted of the sequential combination of DAC followed by low-dose idarubicin/cytarabine in high-risk myeloid neoplasms. A total of 30 patients with a diagnosis of high-risk MDS, AML evolving from MDS or relapsed/refractory AML were enrolled in the study. DAC was administered 20 mg/m(2) daily for 3 consecutive days. Idarubicin (3 mg/m(2)/day) was administered 24 h after the last administration of DAC for 5-7 consecutive days, combined with cytarabine (30 mg/m(2)/day) for 7-14 days. The overall complete remission rate was 66.67%. The results demonstrate that epigenetic priming with decitabine followed by low-dose idarubicin/ytarabine has an increased anti-leukemia effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Authors	Xing-Nong Ye, Xin-Ping Zhou, Ju-Ying Wei, Gai-Xiang Xu, Ying Li, Li-Ping Mao, Jian Huang, Yan-Ling Ren, Chen Mei, Jing-Han Wang, Yin-Jun Lou, Li-Ya Ma, Wen-Juan Yu, Li Ye, Li-Li Xie, Yin-Wan Luo, Chao Hu, Lin-Mei Niu, Min-Hua Dou, Jie Jin, Hong-Yan Tong
Journal	Leukemia & lymphoma (Leuk Lymphoma) Vol. 57 Issue 6 Pg. 1311-8 ( 2016) ISSN: 1029-2403 [Electronic] United States
PMID	26372888 (Publication Type: Journal Article)
Chemical References	Cytarabine Decitabine Azacitidine Idarubicin
Topics	Adult Aged Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use) Azacitidine (administration & dosage, analogs & derivatives, therapeutic use) Chromosome Aberrations Cytarabine (administration & dosage) Decitabine Disease Progression Drug Administration Schedule Drug Resistance, Neoplasm Epigenesis, Genetic (drug effects) Female Humans Idarubicin (administration & dosage) Leukemia, Myeloid, Acute (diagnosis, drug therapy, genetics) Male Middle Aged Mutation Myelodysplastic Syndromes (diagnosis, drug therapy, genetics) Recurrence Remission Induction Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!